Therapy Areas: Allergy
AstraZeneca wins US FDA approval for Tezspire in chronic rhinosinusitis with nasal polyps
20 October 2025 - Biopharmaceutical company AstraZeneca PLC (LSE: AZN) (STO: AZN) (Nasdaq: AZN) announced on Monday that it has received US Food and Drug Administration (FDA) approval for Tezspire (te...
Appili Therapeutics and Vitalex Biosciences secure NIAID contract for fungal vaccine development for up to USD40m
...
ALK partners with GenSci to expand allergy immunotherapy market in China
17 September 2025 - Danish pharmaceutical company ALK-Abelló A/S (ALK) (CPH:ALK-B) said on Wednesday that it has agreed a partnership with Chinese biopharmaceutical company Changchun GeneScienc...
Ionis publishes positive Phase 3 data supporting donidalorsen as HAE prophylactic
21 July 2025 - Ionis Pharmaceuticals Inc (Nasdaq: IONS) on Monday announced the publication of positive Phase 3 OASISplus data in The Journal of Allergy and Clinical Immunology (JACI) In Practice, sup...
Blacksmith Medicines granted US patent for antibacterial compounds targeting LpxC
2 July 2025 - Blacksmith Medicines Inc, a California-based biopharma company involved in discovering and developing therapeutics targeting metalloenzymes, announced on Tuesday that the United States P...
Alvotech reports positive topline results for Xolair biosimilar study
25 June 2025 - European biotech company Alvotech S.A. (NASDAQ:ALVO), US-based biopharmaceutical company Kashiv Biosciences LLC and Advanz Pharma, a UK-based pharmaceutical company with a focus on spec...